News
Jonathan Silverberg, MD, PHD, MPHS, talks about the exciting highlights of the Revolutionizing Atopic Dermatitis virtual conference on December 11.
Activities that can contribute to alterations in skin flora or skin dysbiosis include topical application of steroids, antibiotics, retinoids, harsh soaps, chemical and physical exfoliants, and resurfacing techniques.
Immunomodulator Considerations in Cosmetic Dermatology
A common disorder that is uncommonly discussed, lichen planus may be best addressed with creativity and off-label treatments.
A review of Vishal Anil Patel, MD's presentation on SCC staging underscores the importance of risk stratification in patients.
Patients could soon have access to a new injectable drug to treat atopic dermatitis, the most common form of eczema.
Dr. Friedman reviews one of his sessions from the AAD 2023 Annual Meeting, in which he discussed dysbiosis of the skin and how this contributes to inflammatory skin diseases.
Findings from a mouse model suggest that encapsulating anandamide, an endocannabinoid, could be a way to make it an effective treatment for cutaneous lupus erythematosus (CLE).
Faculty, residents, and students from the George Washington University (GW) School of Medicine and Health Sciences (SMHS) Department of Dermatology had a large-scale, high-impact presence at the 2023 American Academy of Dermatology (AAD) Meeting, March 17–21 in New Orleans, Louisiana.
A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.